ROXITROMYCINE VERSUS DOXYCYCLINE IN THE TREATMENT OF CERVICITIS DUE TO CHLAMYDIA-TRACHOMATIS IN ASYMPTOMATICS WOMEN

We have performed an experimental open study, non randomized, in a pop ulation of women pertaining to a family planning center, and who have been diagnosed of Chlamydia trachomatis infection through EIA and DNA probe. 75 patients were included in the study, 50 of them received rox itromycine; 150 mg every 12 hours during 10 days, the other 25 being t reated with doxycycline, 100 mg each 24 hours during 10 days. All wome n underwent a control after treatment using both techniques a month la ter, to asses the efficacy of the treatment. Mean age of women treated with roxitromycine was 28.6 years, and 30 years the ones treated with doxycycline. Efficacy in the eradication of Chlamydia trachomatis was 91.7% in the group treated with macrolide, and 92% in the group treat ed with doxycycline. Comparison through Chi-square did not yield stati stical significance with a p<0.05. Only a patient treated with doxycyc line showed gastric intolerance. Roxitromycine shows an in vivo activi ty similar to doxycycline, and is an alternative to the use of doxycyc line, being the first choice in those women in whom tetracycline are c ontraindicated.